Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Amsterdam  >  Probiodrug    PBD   DE0007921835

PROBIODRUG (PBD)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
01/11/2018 01/12/2018 01/15/2018 01/16/2018 01/17/2018 Date
14.1(c) 16(c) 17(c) 14.3(c) 13.35(c) Last
127 539 280 146 264 405 261 960 220 638 Volume
+6.82% +13.48% +6.25% -15.88% -6.64% Change
More quotes
Financials (€)
Sales 2017 25,0 M
EBIT 2017 -11,4 M
Net income 2017 -8,64 M
Finance 2017 9,63 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -7,08 M
Net income 2018 -5,85 M
Finance 2018 1,23 M
Yield 2018 -
P/E ratio 2017 6,10
P/E ratio 2018
EV / Sales2017 4,31x
EV / Sales2018 0
Capitalization 117 M
More Financials
Company
Probiodrug AG is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease.Its product pipeline includes PQ912, PBD-C06, and PQ1565.The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and... 
More about the company
Surperformance© ratings of Probiodrug
Trading Rating : Investor Rating : -
More Ratings
Latest news on PROBIODRUG
2017 PROBIODRUG AG : Probiodrug and Crossbeta Biosciences extend their strategic part..
2017 PROBIODRUG AG : Probiodrug and Crossbeta Biosciences extend their strategic part..
2017 PROBIODRUG AG : Probiodrug reports Third Quarter 2017 Business Update
2017PROBIODRUG AG : quaterly sales release
2017 PROBIODRUG : Probiodrug AG to Publish its Third Quarter 2017 Business Update on ..
2017 PROBIODRUG : to Present Data from its Phase 2a SAPHIR Study at International Alz..
2017 PROBIODRUG : initiates Phase 2b core program of PQ912 and details further strate..
2017 PROBIODRUG : initiates Phase 2b core program of PQ912 and details further strate..
2017 PROBIODRUG : New Findings from Probiodrug AG Describe Advances in Inflammation M..
2017 PROBIODRUG : reports financial results for H1 2017 and corporate update
More news
Sector news : Biotechnology & Medical Research - NEC
02:48a CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2017goetzpartners securities Limited: Probiodrug (PBD-NA): Q3 positive, Phase IIb.. 
2017Probiodrug : to Publish its Third Quarter 2017 Business Update on 30 November.. 
2017Probiodrug AG 2017 Q2 - Results - Earnings Call Slides  
2017Probiodrug : to present and attend at International Conferences in September .. 
2017Press Release: Probiodrug AG to Publish First Half 2017 Results on 31 August .. 
More tweets
Qtime:14
News from SeekingAlpha
2017 Probiodrug AG 2017 Q2 - Results - Earnings Call Slides
2017 SNIPPET ROUNDUP : Novartis Enters Advair Generic Race, Biogen Dealt CFO Blow
2017 Biomarin's Rare Disease Approval And Probiodrug's Alzheimer's Play
2015 BP Energy Outlook 2035 Shows More Work Needs To Be Done On Carbon Reduction
Chart PROBIODRUG
Duration : Period :
Probiodrug Technical Analysis Chart | PBD | DE0007921835 | 4-Traders
Technical analysis trends PROBIODRUG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 31,5 €
Spread / Average Target 120%
EPS Revisions
Managers
NameTitle
Konrad Glund Chief Executive Officer
Erich Maximilian Platzer Chairman-Supervisory Board
Hendrik Liebers Chief Financial Officer
Inge Lues Chief Development Officer
Jörg Neermann Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
PROBIODRUG34.91%144
CELLTRION, INC.--.--%41 248
IQVIA HOLDINGS INC2.19%20 807
LONZA GROUP0.42%20 432
INCYTE CORPORATION-0.68%19 852
ALNYLAM PHARMACEUTICALS, INC.1.59%12 692